如何评估与治疗重症监护室患者的血小板减少症
综述重症监护室(ICU)患者血小板减少的多重病因(假性血小板减少、血液稀释、消耗增加、生成减少、 sequestration增加及免疫介导破坏),指出持续血小板减少与死亡率增加相关但非因果关系;识别病因是管理关键,血小板输注在生成受损或破坏增加时可能适用,但在血管内血小板激活增加时可能有害;脓毒症和创伤是最常见原因,治疗原发病可提升血小板计数。
要点
- ICU血小板减少病因多样,识别病因是管理关键。
- 脓毒症和创伤是最常见原因,治疗原发病可提升血小板。
- 血小板输注在生成受损或破坏增加时可能适用,血管内激活增加时可能有害。
核心结论
- 持续血小板减少与重症患者死亡率增加相关,但非因果关系。
- 识别潜在病因是个体患者管理决策的关键。
- 血小板输注在血小板生成受损或破坏增加时可能适用,但在血管内血小板激活增加时可能有害。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 脓毒症和创伤是ICU血小板减少最常见原因,治疗原发病可提升血小板计数。
- 肝素诱导的血小板减少症需治疗剂量的替代抗凝,免疫性血小板减少症需免疫调节治疗。
- 世界卫生组织2级或以上症状性出血或计划侵入性操作是血小板输注的既定指征,预防性血小板输注获益证据弱且有争议。
- 输注2个新鲜ABO同型血小板浓缩物(治疗单位)后血小板计数不增加,应考虑持续血小板消耗和高滴度抗HLA I类抗体,后者需输注HLA相容血小板浓缩物。
关键数值与推荐
- 世界卫生组织2级或以上症状性出血或计划侵入性操作是血小板输注的既定指征。
- 预防性血小板输注获益证据弱且有争议。
- 输注2个新鲜ABO同型血小板浓缩物(治疗单位)后血小板计数不增加,应考虑持续血小板消耗和高滴度抗HLA I类抗体。
临床怎么用
- ICU血小板减少患者应识别潜在病因以指导管理决策。
- 脓毒症和创伤患者治疗原发病可提升血小板计数。
- 肝素诱导的血小板减少症需治疗剂量的替代抗凝。
- 免疫性血小板减少症需免疫调节治疗。
- 世界卫生组织2级或以上症状性出血或计划侵入性操作时输注血小板。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple causes (pseudothrombocytopenia, hemodilution, increased consumption, decreased production, increased sequestration, and immune-mediated destruction of platelets) alone or in combination make thrombocytopenia very common in intensive care unit (ICU) patients. Persisting thrombocytopenia in critically ill patients is associated with, but not causative of, increased mortality. Identification of the underlying cause is key for management decisions in individual patients. While platelet transfusion might be indicated in patients with impaired platelet production or increased platelet destruction, it could be deleterious in patients with increased intravascular platelet activation. Sepsis and trauma are the most common causes of thrombocytopenia in the ICU. In these patients, treatment of the underlying disease will also increase platelet counts. Heparin-induced thrombocytopenia requires alternative anticoagulation at a therapeutic dose and immune thrombocytopenia immunomodulatory treatment. Thrombocytopenia with symptomatic bleeding at or above World Health Organization grade 2 or planned invasive procedures are established indications for platelet transfusions, while the evidence for a benefit of prophylactic platelet transfusions is weak and controversial. If the platelet count does not increase after transfusion of 2 fresh ABO blood group-identical platelet concentrates (therapeutic units), ongoing platelet consumption and high-titer anti-HLA class I antibodies should be considered. The latter requires transfusion of HLA-compatible platelet concentrates.
引用
- Greinacher A, Selleng S. How I evaluate and treat thrombocytopenia in the intensive care unit patient. Blood. 2016. PMID: 28034871. doi:10.1182/blood-2016-09-693655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。